{
  "source": "PA-Notification-Camzyos.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1391-3\nProgram Prior Authorization/Notification\nMedication Camzyos® (mavacamten)\nP&T Approval Date 7/2022, 8/2023, 8/2024\nEffective Date 11/1/2024\n1. Background:\nCamzyos® (mavacamten) is a cardiac myosin inhibitor indicated for the treatment of adults with\nsymptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic\ncardiomyopathy (HCM) to improve functional capacity and symptoms.1\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Camzyos will be approved based on both of the following:\na. Diagnosis of obstructive hypertrophic cardiomyopathy (HCM)\n-AND-\nb. Heart failure is classified as one of the following:\n(1) New York Heart Association (NYHA) class II heart failure\n-OR-\n(2) New York Heart Association (NYHA) class III heart failure\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Camzyos will be approved based upon the following criterion:\na. Documentation of positive clinical response to Camzyos therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits and/or Medical Necessity may be in place.\n4. References:\n1. Camzyos® [package insert]. Brisbane, CA: Bristol Myers Squibb; April 2024.\nProgram Prior Authorization/Notification – Camzyos® (mavacamten)\nChange Control\n7/2022 New program.\n8/2023 Annual review. Updated reference.\n8/2024 Annual review. Added Med Nec may be in place under addit",
    "ram Prior Authorization/Notification – Camzyos® (mavacamten)\nChange Control\n7/2022 New program.\n8/2023 Annual review. Updated reference.\n8/2024 Annual review. Added Med Nec may be in place under additional clinical\nrules. Updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}